Retinal vein occlusion (RVO) is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema. Different treatment modalities for macular edema include LASER therapy, antivascular endothelial growth factor (VEGF), and triamcinolone. Aim To detect the efficacy of formulated Triamcinolone Acetonide(TA) injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Best corrected visual acuity
Timeframe: at the base line
Best corrected visual acuity
Timeframe: at 1st month
Best corrected visual acuity
Timeframe: at 3rd month
Best corrected visual acuity
Timeframe: at 6th month
Central macular thickness
Timeframe: at 1st month
Central macular thickness
Timeframe: at 3rd month
Central macular thickness
Timeframe: at 6th month